Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00860275 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
A Phase 1 study of Alzheimer Disease, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00860275 is a Phase 1 study of Alzheimer Disease that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 30 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00860275, a Phase 1 study of Alzheimer Disease, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine if the concomitant administration of either ketoconazole or fluconazole with BMS-708163 will affect the PK of BMS-708163 and to assess safety and tolerability of BMS-708163
Conditions Studied
Interventions
- DRUG Fluconazole
- DRUG Ketoconazole
- DRUG BMS-708163
- DRUG BMS-708163 + Ketoconazole
- DRUG BMS-708163 + Fluconazole
Study Locations (1)
Texas
- Ppd Development, Lp - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00860275
The ClinicalTrials.gov registry entry for NCT00860275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Fluconazole is the first listed.
NCT00860275 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00860275 about?
NCT00860275 is a clinical study titled "Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole". The purpose of the study is to determine if the concomitant administration of either ketoconazole or fluconazole with BMS-708163 will affect the PK of BMS-708163 and to assess safety and tolerability of BMS-708163
What is the current status of trial NCT00860275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2009-06.
What conditions does trial NCT00860275 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT00860275?
The interventions under investigation include: Fluconazole (DRUG), Ketoconazole (DRUG), BMS-708163 (DRUG), BMS-708163 + Ketoconazole (DRUG), BMS-708163 + Fluconazole (DRUG).
Who is sponsoring clinical trial NCT00860275?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00860275 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.